Skip to content

    Sai Life

    SAILIFEGood
    Healthcare·7 Nov 2025
    Management Summary

    Sai Life Sciences delivered a robust H1 FY26 performance characterized by significant revenue growth and margin expansion, primarily driven by the scaling of late-stage and commercial programs in the CDMO segment. The company is aggressively investing in capacity and new technology modalities like peptides, ADCs, and oligonucleotides to capitalize on the 'China+1' supply chain rebalancing trend. Management remains confident in sustaining high growth rates and improving profitability through operational efficiencies and asset productivity.

    Highlights

    8

    • Total revenue for H1 FY26 reached ₹1,034 crores, representing a 53% YoY increase.

    • EBITDA grew by 101% YoY to ₹281 crores, with margins expanding 650 bps to 27%.

    • CDMO business revenue surged 72% YoY to ₹667 crores, contributing 64% of total revenue.

    • CRO business revenue grew 28% YoY to ₹367 crores, despite a perceived slowdown in biotech funding.

    • PAT for the H1 period stood at ₹144 crores.

    • Management maintained a long-term revenue growth guidance of 15-20% over a 3-5 year period.

    • Planned capex of ₹700 crores for FY26, with ₹248 crores already incurred in H1.

    • Capacity expansion on track to reach 1,150 KL by the end of FY27 from the current ~700 KL.

    What Changed2

    vs Q3 FY26

    Guidance items8 → 4 (-4)Q&A highlights8 → 3 (-5)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹1,034 Cr+53%YoY
    2. 02EBITDA₹281 Cr+101%YoY
    3. 03EBITDA Margin27%
    4. 04PAT₹144 Cr
    5. 05Capex₹248 Cr

    Segment breakdown

    • CDMO Business₹667 Cr64.5%
    • CRO Business₹367 Cr35.5%
    Donut· Share of Revenue

    Guidance & targets

    4
    CategoryTargetPriority
    Revenue
    Revenue Growth
    15-20%
    		High
    Margin
    EBITDA Margin
    28-30%
    		Medium
    Capex
    Total Capex
    ₹700 crores
    		High
    Capacity
    Installed Capacity
    1150 KL
    		High

    Risks & concerns

    6
    RiskSeverity

    Biotech Funding Slowdown

    Management admits a perceived slowdown in biotech funding is impacting the innovation pipeline, though they claim to offset this with large pharma clients. — Both acknowledged

    medium

    Product Concentration

    Analysts raised concerns about concentration in the CDMO business; management argues they work with 18 of the top 25 pharma companies to mitigate this. — Analyst downplayed

    medium

    Geopolitical Supply Chain Risks

    Concentration in a single geography (China) is seen as a risk by clients, which Sai is positioning to benefit from via 'China+1'. — Management acknowledged

    low

    Areas of Evasion(3)

    • Specific success metrics for proprietary collaborations
    • Exact clinical readout timelines for Phase III pipeline
    • Specific capex numbers beyond FY26

    Q&A highlights

    3

    “There is an increase in gross margin on account of operational efficiency that we gained on certain commercial products between the period.”

    Clarifies that margin gains are structural/operational rather than one-off gains or just segment mix shifts.

    asked by Binay Singh, Morgan Stanley

    2 min read4 chapters

    Detailed Narrative

    01

    Stellar H1 Performance Driven by CDMO Scaling

    Sai Life Sciences reported a 53% YoY revenue jump to ₹1,034 crores for H1 FY26, with the CDMO segment growing at a faster clip of 72%. This growth is underpinned by the continuous scale-up of late-stage and commercial programs. EBITDA margins saw a significant expansion of 650 bps to 27%, driven by better asset utilization and operational efficiencies in commercial products. Management is targeting a sustainable EBITDA margin band of 28-30% as they continue to optimize their cost structure.

    02

    Aggressive Capacity Expansion to Meet Global Demand

    The company is on a clear path to expand its manufacturing footprint, aiming to increase total installed capacity from 700 KL to 1,150 KL by the end of FY27. To support this, Sai has planned a total capex of ₹700 crores for FY26, of which ₹248 crores was deployed in the first half. This investment is not just for volume but also for technological depth, including new facilities for Veterinary APIs and expanded preclinical assay capabilities at the Hyderabad R&D Center.

    03

    Strategic Pivot to New Modalities and Technologies

    Sai is deepening its capabilities in complex therapeutics, specifically peptides, ADCs, and oligonucleotides. They have commenced long-term collaborations with large pharma on linker chemistry for ADCs and are validating a phosphoramidite process for commercial oligonucleotides. Management emphasizes a 'strategic collaborator' model, working on proprietary client platforms rather than offering generic standalone products, which they believe creates higher stickiness and long-term value.

    04

    Navigating Macro Headwinds: China+1 and Biotech Funding

    While acknowledging a slowdown in biotech funding, management noted that increased engagement with large pharma innovators has more than compensated for the impact. The 'China+1' trend remains a significant tailwind as global companies seek to rebalance supply chains away from single-geography concentration. Sai's presence in the US (biology center) and UK (API development) further strengthens its position as an integrated global CRDMO capable of serving clients across the entire development value chain.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.